☰

William T. Dauer - Publications

Affiliations: 
Columbia University, New York, NY 
Area:
neurology
Tree Info Grants Similar researchers PubMed Report error

59/116 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Li J, Levin DS, Kim AJ, Pappas SS, Dauer WT. TorsinA restoration in a mouse model identifies a critical therapeutic window for DYT1 dystonia. The Journal of Clinical Investigation. PMID 33529159 DOI: 10.1172/JCI139606  0.349
2020 Li J, Liang CC, Pappas SS, Dauer WT. TorsinB overexpression prevents abnormal twisting in DYT1 dystonia mouse models. Elife. 9. PMID 32202496 DOI: 10.7554/Elife.54285  0.461
2019 Shin JY, Hernandez-Ono A, Fedotova T, Östlund C, Lee MJ, Gibeley SB, Liang CC, Dauer WT, Ginsberg HN, Worman HJ. Nuclear envelope-localized torsinA-LAP1 complex regulates hepatic VLDL secretion and steatosis. The Journal of Clinical Investigation. 130. PMID 31408437 DOI: 10.1172/Jci129769  0.315
2019 Bohnen NI, Kanel P, Zhou Z, Koeppe RA, Frey KA, Dauer WT, Albin RL, Müller MLTM. Cholinergic system changes of falls and freezing of gait in Parkinson disease. Annals of Neurology. PMID 30720884 DOI: 10.1002/Ana.25430  0.33
2018 Albin RL, Surmeier DJ, Tubert C, Sarter M, Müller MLTM, Bohnen NI, Dauer WT. Targeting the pedunculopontine nucleus in Parkinson's disease: Time to go back to the drawing board. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 30398673 DOI: 10.1002/mds.27540  0.366
2018 Pappas SS, Li J, LeWitt TM, Kim JK, Monani UR, Dauer WT. A cell autonomous torsinA requirement for cholinergic neuron survival and motor control. Elife. 7. PMID 30117805 DOI: 10.7554/Elife.36691  0.409
2018 Antoniou N, Vlachakis D, Memou A, Leandrou E, Valkimadi PE, Melachroinou K, Re DB, Przedborski S, Dauer WT, Stefanis L, Rideout HJ. A motif within the armadillo repeat of Parkinson's-linked LRRK2 interacts with FADD to hijack the extrinsic death pathway. Scientific Reports. 8: 3455. PMID 29472595 DOI: 10.1038/S41598-018-21931-8  0.369
2018 Weisheit CE, Pappas SS, Dauer WT. Inherited dystonias: clinical features and molecular pathways. Handbook of Clinical Neurology. 147: 241-254. PMID 29325615 DOI: 10.1016/B978-0-444-63233-3.00016-6  0.45
2018 Pappas SS, Li J, LeWitt TM, Kim J, Monani UR, Dauer WT. Author response: A cell autonomous torsinA requirement for cholinergic neuron survival and motor control Elife. DOI: 10.7554/Elife.36691.024  0.311
2017 Pappas SS, Liang CC, Kim S, Rivera CO, Dauer WT. TorsinA dysfunction causes persistent neuronal nuclear pore defects. Human Molecular Genetics. PMID 29186574 DOI: 10.1093/Hmg/Ddx405  0.452
2017 Yellajoshyula D, Liang CC, Pappas SS, Penati S, Yang A, Mecano R, Kumaran R, Jou S, Cookson MR, Dauer WT. The DYT6 Dystonia Protein THAP1 Regulates Myelination within the Oligodendrocyte Lineage. Developmental Cell. 42: 52-67.e4. PMID 28697333 DOI: 10.1016/J.Devcel.2017.06.009  0.375
2017 DeSimone JC, Pappas SS, Febo M, Burciu RG, Shukla P, Colon-Perez LM, Dauer WT, Vaillancourt DE. Forebrain knock-out of torsinA reduces striatal free-water and impairs whole-brain functional connectivity in a symptomatic mouse model of DYT1 dystonia. Neurobiology of Disease. PMID 28673740 DOI: 10.1016/J.Nbd.2017.06.015  0.438
2016 Shin JY, Méndez-López I, Hong M, Wang Y, Tanji K, Wu W, Shugol L, Krauss RS, Dauer WT, Worman HJ. Lamina-associated polypeptide 1 is dispensable for embryonic myogenesis but required for postnatal skeletal muscle growth. Human Molecular Genetics. PMID 27798115 DOI: 10.1093/Hmg/Ddw368  0.32
2016 Shakkottai VG, Batla A, Bhatia K, Dauer WT, Dresel C, Niethammer M, Eidelberg D, Raike RS, Smith Y, Jinnah HA, Hess EJ, Meunier S, Hallett M, Fremont R, Khodakhah K, et al. Current Opinions and Areas of Consensus on the Role of the Cerebellum in Dystonia. Cerebellum (London, England). PMID 27734238 DOI: 10.1007/S12311-016-0825-6  0.411
2016 Tanabe LM, Liang CC, Dauer WT. Neuronal Nuclear Membrane Budding Occurs during a Developmental Window Modulated by Torsin Paralogs. Cell Reports. 16: 3322-33. PMID 27653693 DOI: 10.1016/J.Celrep.2016.08.044  0.737
2016 Kett LR, Dauer WT. Endolysosomal dysfunction in Parkinson's disease: Recent developments and future challenges. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 27619535 DOI: 10.1002/mds.26797  0.419
2016 Dinov ID, Heavner B, Tang M, Glusman G, Chard K, Darcy M, Madduri R, Pa J, Spino C, Kesselman C, Foster I, Deutsch EW, Price ND, Van Horn JD, Ames J, ... ... Dauer W, et al. Predictive Big Data Analytics: A Study of Parkinson's Disease Using Large, Complex, Heterogeneous, Incongruent, Multi-Source and Incomplete Observations. Plos One. 11: e0157077. PMID 27494614 DOI: 10.1371/Journal.Pone.0157077  0.318
2015 Jankovic J, Bressman S, Dauer W, Kang UJ. Clinical and scientific perspectives on movement disorders: Stanley Fahn's contributions. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 1862-9. PMID 26477883 DOI: 10.1002/Mds.26445  0.322
2015 Weisheit CE, Dauer WT. A novel conditional knock-in approach defines molecular and circuit effects of the DYT1 dystonia mutation. Human Molecular Genetics. 24: 6459-72. PMID 26370418 DOI: 10.1093/hmg/ddv355  0.429
2015 Goodchild RE, Buchwalter AL, Naismith TV, Holbrook K, Billion K, Dauer WT, Liang CC, Dear ML, Hanson PI. Access of torsinA to the inner nuclear membrane is activity dependent and regulated in the endoplasmic reticulum. Journal of Cell Science. PMID 26092934 DOI: 10.1242/Jcs.167452  0.313
2015 Pappas SS, Darr K, Holley SM, Cepeda C, Mabrouk OS, Wong JM, LeWitt TM, Paudel R, Houlden H, Kennedy RT, Levine MS, Dauer WT. Forebrain deletion of the dystonia protein torsinA causes dystonic-like movements and loss of striatal cholinergic neurons. Elife. 4. PMID 26052670 DOI: 10.7554/Elife.08352  0.427
2015 Kett LR, Stiller B, Bernath MM, Tasset I, Blesa J, Jackson-Lewis V, Chan RB, Zhou B, Di Paolo G, Przedborski S, Cuervo AM, Dauer WT. α-Synuclein-independent histopathological and motor deficits in mice lacking the endolysosomal Parkinsonism protein Atp13a2. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 35: 5724-42. PMID 25855184 DOI: 10.1523/Jneurosci.0632-14.2015  0.457
2015 VanGompel MJ, Nguyen KC, Hall DH, Dauer WT, Rose LS. A novel function for the Caenorhabditis elegans torsin OOC-5 in nucleoporin localization and nuclear import. Molecular Biology of the Cell. 26: 1752-63. PMID 25739455 DOI: 10.1091/Mbc.E14-07-1239  0.428
2015 Dauer W. Inherited isolated dystonia: clinical genetics and gene function. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 11: 807-16. PMID 25155315 DOI: 10.1007/s13311-014-0297-7  0.346
2015 Dauer W. Inherited isolated dystonia: clinical genetics and gene function. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 11: 807-16. PMID 25155315 DOI: 10.1007/s13311-014-0297-7  0.346
2015 Pappas SS, Darr K, Holley SM, Cepeda C, Mabrouk OS, Wong JT, LeWitt TM, Paudel R, Houlden H, Kennedy RT, Levine MS, Dauer WT. Author response: Forebrain deletion of the dystonia protein torsinA causes dystonic-like movements and loss of striatal cholinergic neurons Elife. DOI: 10.7554/Elife.08352.023  0.372
2014 Bohnen NI, Müller MLTM, Dauer WT, Albin RL. Parkinson's Disease: What role do pedunculopontine nucleus cholinergic neurons play? Future Neurology. 9: 5-8. PMID 28845134 DOI: 10.2217/fnl.13.61  0.372
2014 Dauer WT. Neurogenetic disease: genes, mechanisms, and future promise. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 11: 697-8. PMID 25261113 DOI: 10.1007/s13311-014-0303-0  0.407
2014 Worman HJ, Dauer WT. The nuclear envelope: an intriguing focal point for neurogenetic disease. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 11: 764-72. PMID 25119890 DOI: 10.1007/S13311-014-0296-8  0.404
2014 Maric M, Haugo AC, Dauer W, Johnson D, Roller RJ. Nuclear envelope breakdown induced by herpes simplex virus type 1 involves the activity of viral fusion proteins. Virology. 460: 128-37. PMID 25010278 DOI: 10.1016/J.Virol.2014.05.010  0.305
2014 Pappas SS, Leventhal DK, Albin RL, Dauer WT. Mouse models of neurodevelopmental disease of the basal ganglia and associated circuits. Current Topics in Developmental Biology. 109: 97-169. PMID 24947237 DOI: 10.1016/B978-0-12-397920-9.00001-9  0.41
2014 Liang CC, Tanabe LM, Jou S, Chi F, Dauer WT. TorsinA hypofunction causes abnormal twisting movements and sensorimotor circuit neurodegeneration. The Journal of Clinical Investigation. 124: 3080-92. PMID 24937429 DOI: 10.1172/Jci72830  0.754
2014 Shin JY, Le Dour C, Sera F, Iwata S, Homma S, Joseph LC, Morrow JP, Dauer WT, Worman HJ. Depletion of lamina-associated polypeptide 1 from cardiomyocytes causes cardiac dysfunction in mice. Nucleus (Austin, Tex.). 5: 260-459. PMID 24859316 DOI: 10.4161/Nucl.29227  0.359
2014 Mehanna R, Bohnen N, Sarter M, Muller M, Dauer W, Albin R, Arbor A. Gait speed in Parkinson disease correlates with cholinergic degenerationAuthor Response Neurology. 82: 1568-1569. PMID 24778286 DOI: 10.1212/01.Wnl.0000446971.02565.F1  0.328
2014 Albin RL, Dauer WT. Magic shotgun for Parkinson's disease? Brain : a Journal of Neurology. 137: 1274-5. PMID 24771397 DOI: 10.1093/brain/awu076  0.355
2014 Dauer WT, Guo M. Multiplying messages LRRK beneath Parkinson disease. Cell. 157: 291-3. PMID 24725399 DOI: 10.1016/j.cell.2014.03.043  0.359
2014 Shin JY, Dauer WT, Worman HJ. Lamina-associated polypeptide 1: protein interactions and tissue-selective functions. Seminars in Cell & Developmental Biology. 29: 164-8. PMID 24508913 DOI: 10.1016/J.Semcdb.2014.01.010  0.422
2013 Santos M, Rebelo S, Van Kleeff PJ, Kim CE, Dauer WT, Fardilha M, da Cruz E Silva OA, da Cruz E Silva EF. The nuclear envelope protein, LAP1B, is a novel protein phosphatase 1 substrate. Plos One. 8: e76788. PMID 24116158 DOI: 10.1371/Journal.Pone.0076788  0.57
2013 Shin JY, Méndez-López I, Wang Y, Hays AP, Tanji K, Lefkowitch JH, Schulze PC, Worman HJ, Dauer WT. Lamina-associated polypeptide-1 interacts with the muscular dystrophy protein emerin and is essential for skeletal muscle maintenance. Developmental Cell. 26: 591-603. PMID 24055652 DOI: 10.1016/J.Devcel.2013.08.012  0.354
2013 Ledoux MS, Dauer WT, Warner TT. Emerging common molecular pathways for primary dystonia. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 968-81. PMID 23893453 DOI: 10.1002/mds.25547  0.404
2013 Orenstein SJ, Kuo SH, Tasset I, Arias E, Koga H, Fernandez-Carasa I, Cortes E, Honig LS, Dauer W, Consiglio A, Raya A, Sulzer D, Cuervo AM. Interplay of LRRK2 with chaperone-mediated autophagy. Nature Neuroscience. 16: 394-406. PMID 23455607 DOI: 10.1038/Nn.3350  0.464
2012 Albin RL, Dauer WT. Parkinson syndrome. Heterogeneity of etiology; heterogeneity of pathogenesis? Neurology. 79: 202-3. PMID 22722622 DOI: 10.1212/WNL.0b013e31825dd3d0  0.392
2012 Kett LR, Dauer WT. Leucine-rich repeat kinase 2 for beginners: six key questions. Cold Spring Harbor Perspectives in Medicine. 2: a009407. PMID 22393539 DOI: 10.1101/cshperspect.a009407  0.345
2012 Tanabe LM, Martin C, Dauer WT. Genetic background modulates the phenotype of a mouse model of DYT1 dystonia. Plos One. 7: e32245. PMID 22393392 DOI: 10.1371/Journal.Pone.0032245  0.739
2012 Kett LR, Boassa D, Ho CC, Rideout HJ, Hu J, Terada M, Ellisman M, Dauer WT. LRRK2 Parkinson disease mutations enhance its microtubule association. Human Molecular Genetics. 21: 890-9. PMID 22080837 DOI: 10.1093/Hmg/Ddr526  0.625
2011 Droggiti A, Ho CC, Stefanis L, Dauer WT, Rideout HJ. Targeted disruption of neuronal 19S proteasome subunits induces the formation of ubiquitinated inclusions in the absence of cell death. Journal of Neurochemistry. 119: 630-43. PMID 21883213 DOI: 10.1111/j.1471-4159.2011.07444.x  0.588
2011 UluÄŸ AM, Vo A, Argyelan M, Tanabe L, Schiffer WK, Dewey S, Dauer WT, Eidelberg D. Cerebellothalamocortical pathway abnormalities in torsinA DYT1 knock-in mice. Proceedings of the National Academy of Sciences of the United States of America. 108: 6638-43. PMID 21464304 DOI: 10.1073/Pnas.1016445108  0.761
2011 Martin JN, Wolken N, Brown T, Dauer WT, Ehrlich ME, Gonzalez-Alegre P. Lethal toxicity caused by expression of shRNA in the mouse striatum: implications for therapeutic design. Gene Therapy. 18: 666-73. PMID 21368900 DOI: 10.1038/Gt.2011.10  0.394
2010 Kim CE, Perez A, Perkins G, Ellisman MH, Dauer WT. A molecular mechanism underlying the neural-specific defect in torsinA mutant mice. Proceedings of the National Academy of Sciences of the United States of America. 107: 9861-6. PMID 20457914 DOI: 10.1073/Pnas.0912877107  0.649
2010 Dauer W, Ho CCY. The biology and pathology of the familial Parkinson's disease protein LRRK2 Movement Disorders. 25: S40-S43. PMID 20187256 DOI: 10.1002/mds.22717  0.388
2009 Jorgensen ND, Peng Y, Ho CC, Rideout HJ, Petrey D, Liu P, Dauer WT. The WD40 domain is required for LRRK2 neurotoxicity. Plos One. 4: e8463. PMID 20041156 DOI: 10.1371/Journal.Pone.0008463  0.603
2009 Dauer WT, Worman HJ. The nuclear envelope as a signaling node in development and disease. Developmental Cell. 17: 626-38. PMID 19922868 DOI: 10.1016/J.Devcel.2009.10.016  0.371
2009 Tanabe LM, Kim CE, Alagem N, Dauer WT. Primary dystonia: molecules and mechanisms. Nature Reviews. Neurology. 5: 598-609. PMID 19826400 DOI: 10.1038/Nrneurol.2009.160  0.74
2009 Ho CC, Rideout HJ, Ribe E, Troy CM, Dauer WT. The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 1011-6. PMID 19176810 DOI: 10.1523/JNEUROSCI.5175-08.2009  0.605
2008 Akman HO, Dorado B, López LC, García-Cazorla A, Vilà MR, Tanabe LM, Dauer WT, Bonilla E, Tanji K, Hirano M. Thymidine kinase 2 (H126N) knockin mice show the essential role of balanced deoxynucleotide pools for mitochondrial DNA maintenance. Human Molecular Genetics. 17: 2433-40. PMID 18467430 DOI: 10.1093/Hmg/Ddn143  0.728
2007 Cookson MR, Dauer W, Dawson T, Fon EA, Guo M, Shen J. The roles of kinases in familial Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 11865-8. PMID 17978026 DOI: 10.1523/Jneurosci.3695-07.2007  0.324
2005 Goodchild RE, Kim CE, Dauer WT. Loss of the dystonia-associated protein torsinA selectively disrupts the neuronal nuclear envelope. Neuron. 48: 923-32. PMID 16364897 DOI: 10.1016/J.Neuron.2005.11.010  0.627
2004 Goodchild RE, Dauer WT. Mislocalization to the nuclear envelope: an effect of the dystonia-causing torsinA mutation. Proceedings of the National Academy of Sciences of the United States of America. 101: 847-52. PMID 14711988 DOI: 10.1073/pnas.0304375101  0.378
1988 Bissette G, Dauer WT, Kilts CD, O'Connor L, Nemeroff CB. The effect of the stereoisomers of butaclamol on neurotensin content in discrete regions of the rat brain. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 1: 329-35. PMID 2472151  0.311
Low-probability matches (unlikely to be authored by this person)
2009 Martin JN, Bair TB, Bode N, Dauer WT, Gonzalez-Alegre P. Transcriptional and proteomic profiling in a cellular model of DYT1 dystonia. Neuroscience. 164: 563-72. PMID 19665049 DOI: 10.1016/J.Neuroscience.2009.07.068  0.3
2021 Mitchell SD, Albin RL, Dauer WT, Goudreau JL, Sidiropoulos C. Heterozygous VPS13A and PARK2 Mutations in a Patient with Parkinsonism and Seizures. Case Reports in Neurology. 13: 341-346. PMID 34248567 DOI: 10.1159/000515805  0.294
2010 Dorval T, Ogier A, Genovesio A, Lim HK, Kwon do Y, Lee JH, Worman HJ, Dauer W, Grailhe R. Contextual automated 3D analysis of subcellular organelles adapted to high-content screening. Journal of Biomolecular Screening. 15: 847-57. PMID 20639502 DOI: 10.1177/1087057110374993  0.292
2022 Yellajoshyula D, Pappas SS, Dauer WT. Oligodendrocyte and Extracellular Matrix Contributions to Central Nervous System Motor Function: Implications for Dystonia. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 34989453 DOI: 10.1002/mds.28892  0.292
2020 Li J, Liang C, Pappas SS, Dauer WT. Author response: TorsinB overexpression prevents abnormal twisting in DYT1 dystonia mouse models Elife. DOI: 10.7554/Elife.54285.Sa2  0.288
2022 Yellajoshyula D, Opeyemi S, Dauer WT, Pappas SS. Genetic evidence of aberrant striatal synaptic maturation and secretory pathway alteration in a dystonia mouse model. Dystonia. 1. PMID 36874764 DOI: 10.3389/dyst.2022.10892  0.284
2017 Saunders CA, Harris NJ, Willey PT, Woolums BM, Wang Y, McQuown AJ, Schoenhofen A, Worman HJ, Dauer WT, Gundersen GG, Luxton GW. TorsinA controls TAN line assembly and the retrograde flow of dorsal perinuclear actin cables during rearward nuclear movement. The Journal of Cell Biology. PMID 28242745 DOI: 10.1083/Jcb.201507113  0.283
2018 Gao C, Sun H, Wang T, Tang M, Bohnen NI, Müller MLTM, Herman T, Giladi N, Kalinin A, Spino C, Dauer W, Hausdorff JM, Dinov ID. Model-based and Model-free Machine Learning Techniques for Diagnostic Prediction and Classification of Clinical Outcomes in Parkinson's Disease. Scientific Reports. 8: 7129. PMID 29740058 DOI: 10.1038/S41598-018-24783-4  0.271
2022 Kernodle K, Bakerian AM, Cropsey A, Dauer WT, Leventhal DK. A dystonia mouse model with motor and sequencing deficits paralleling human disease. Behavioural Brain Research. 426: 113844. PMID 35304183 DOI: 10.1016/j.bbr.2022.113844  0.265
2018 Albin RL, Bohnen NI, Muller ML, Dauer WT, Sarter M, Frey KA, Koeppe RA. Regional Vesicular Acetylcholine Transporter Distribution in Human Brain: A [ F]Fluoroethoxybenzovesamicol Positron Emission Tomography Study. The Journal of Comparative Neurology. PMID 30255936 DOI: 10.1002/Cne.24541  0.262
2022 Stormo AED, Shavarebi F, FitzGibbon M, Earley EM, Ahrendt H, Lum LS, Verschueren E, Swaney DL, Skibinski G, Ravisankar A, van Haren J, Davis EJ, Johnson JR, Von Dollen J, Balen C, ... ... Dauer WT, et al. The E3 ligase TRIM1 ubiquitinates LRRK2 and controls its localization, degradation, and toxicity. The Journal of Cell Biology. 221. PMID 35266954 DOI: 10.1083/jcb.202010065  0.259
2008 Zhou C, Huang Y, Shao Y, May J, Prou D, Perier C, Dauer W, Schon EA, Przedborski S. The kinase domain of mitochondrial PINK1 faces the cytoplasm. Proceedings of the National Academy of Sciences of the United States of America. 105: 12022-7. PMID 18687899 DOI: 10.1073/Pnas.0802814105  0.258
2023 Kim S, Phan S, Shaw TR, Ellisman MH, Veatch SL, Barmada SJ, Pappas SS, Dauer WT. TorsinA is essential for the timing and localization of neuronal nuclear pore complex biogenesis. Biorxiv : the Preprint Server For Biology. PMID 37162852 DOI: 10.1101/2023.04.26.538491  0.252
2021 Yellajoshyula D, Rogers AE, Kim AJ, Kim S, Pappas SS, Dauer WT. A pathogenic DYT-THAP1 dystonia mutation causes hypomyelination and loss of YY1 binding. Human Molecular Genetics. PMID 34686877 DOI: 10.1093/hmg/ddab310  0.249
2003 Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron. 39: 889-909. PMID 12971891 DOI: 10.1016/S0896-6273(03)00568-3  0.247
2004 Kholodilov N, Yarygina O, Oo TF, Zhang H, Sulzer D, Dauer W, Burke RE. Regulation of the development of mesencephalic dopaminergic systems by the selective expression of glial cell line-derived neurotrophic factor in their targets. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 3136-46. PMID 15044553 DOI: 10.1523/JNEUROSCI.4506-03.2004  0.239
2001 Yamamoto A, Hen R, Dauer WT. The ons and offs of inducible transgenic technology: a review. Neurobiology of Disease. 8: 923-32. PMID 11741388 DOI: 10.1006/Nbdi.2001.0452  0.237
2002 Dauer W, Kholodilov N, Vila M, Trillat AC, Goodchild R, Larsen KE, Staal R, Tieu K, Schmitz Y, Yuan CA, Rocha M, Jackson-Lewis V, Hersch S, Sulzer D, Przedborski S, et al. Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proceedings of the National Academy of Sciences of the United States of America. 99: 14524-9. PMID 12376616 DOI: 10.1073/Pnas.172514599  0.237
2019 Li J, Dauer W. Cholinergic interneurons drive maladaptive changes in thalamostriatal circuitry after dopamine depletion. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 30938861 DOI: 10.1002/mds.27685  0.235
2021 Bohnen NI, Costa RM, Dauer WT, Factor SA, Giladi N, Hallett M, Lewis SJG, Nieuwboer A, Nutt JG, Takakusaki K, Kang UJ, Przedborski S, Papa SM. Discussion of Research Priorities for Gait Disorders in Parkinson's Disease. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 34939221 DOI: 10.1002/mds.28883  0.232
2014 Bohnen NI, Müller ML, Dauer WT, Albin RL. Parkinsons disease: What role do pedunculopontine cholinergic neurons play? Future Neurology. 9: 5-8. DOI: 10.2217/fnl.13.61  0.232
2008 Burke RE, Dauer WT, Vonsattel JP. A critical evaluation of the Braak staging scheme for Parkinson's disease. Annals of Neurology. 64: 485-91. PMID 19067353 DOI: 10.1002/ana.21541  0.23
2018 Ginsberg H, Shin J, Hernandez-Ono A, Fedotova T, Gilbeley S, Östlund C, Lee M, Dauer W, Worman H. Loss of function of either LAP1 or torsina, nuclear membrane associated proteins, causes inhibition of VLDL secretion and severe steatohepatitis in chow fed mice Atherosclerosis. 275: e65. DOI: 10.1016/j.atherosclerosis.2018.06.177  0.223
2022 Östlund C, Hernandez-Ono A, Turk SJ, Dauer WT, Ginsberg HN, Worman HJ, Shin JY. Hepatocytes deficient in nuclear envelope protein lamina-associated polypeptide 1 are an ideal mammalian system to study intranuclear lipid droplets. Journal of Lipid Research. 100277. PMID 36100089 DOI: 10.1016/j.jlr.2022.100277  0.219
2021 Li J, Kim S, Pappas SS, Dauer WT. CNS critical periods: implications for dystonia and other neurodevelopmental disorders. Jci Insight. 6. PMID 33616084 DOI: 10.1172/jci.insight.142483  0.21
2003 Rideout HJ, Dietrich P, Savalle M, Dauer WT, Stefanis L. Regulation of alpha-synuclein by bFGF in cultured ventral midbrain dopaminergic neurons. Journal of Neurochemistry. 84: 803-13. PMID 12562524 DOI: 10.1046/J.1471-4159.2003.01574.X  0.208
2004 Rideout HJ, Dietrich P, Wang Q, Dauer WT, Stefanis L. alpha-synuclein is required for the fibrillar nature of ubiquitinated inclusions induced by proteasomal inhibition in primary neurons. The Journal of Biological Chemistry. 279: 46915-20. PMID 15322100 DOI: 10.1074/Jbc.M405146200  0.208
2010 Dauer WT, Worman HJ. New messages in the nuclear envelope. Cell Cycle (Georgetown, Tex.). 9: 645-6. PMID 20190576 DOI: 10.4161/Cc.9.4.10844  0.201
2005 Goodchild RE, Dauer WT. The AAA+ protein torsinA interacts with a conserved domain present in LAP1 and a novel ER protein. The Journal of Cell Biology. 168: 855-62. PMID 15767459 DOI: 10.1083/jcb.200411026  0.2
2004 Stefanis L, Wang Q, Oo T, Lang-Rollin I, Burke RE, Dauer WT. Lack of alpha-synuclein does not alter apoptosis of neonatal catecholaminergic neurons. The European Journal of Neuroscience. 20: 1969-72. PMID 15380020 DOI: 10.1111/j.1460-9568.2004.03638.x  0.19
2007 Dauer W. Neurotrophic factors and Parkinson's disease: the emergence of a new player? Science's Stke : Signal Transduction Knowledge Environment. 2007: pe60. PMID 17986711 DOI: 10.1126/stke.4112007pe60  0.187
2008 Martinez-Vicente M, Talloczy Z, Kaushik S, Massey AC, Mazzulli J, Mosharov EV, Hodara R, Fredenburg R, Wu DC, Follenzi A, Dauer W, Przedborski S, Ischiropoulos H, Lansbury PT, Sulzer D, et al. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. The Journal of Clinical Investigation. 118: 777-88. PMID 18172548 DOI: 10.1172/Jci32806  0.184
2017 Pappas SS, Bonifacino J, Danek A, Dauer WT, De M, De Franceschi L, DiPaolo G, Fuller R, Haucke V, Hermann A, Kornmann B, Landwehrmeyer B, Levin J, Neiman AM, Rudnicki DD, et al. Eighth International Chorea-Acanthocytosis Symposium: Summary of Workshop Discussion and Action Points. Tremor and Other Hyperkinetic Movements (New York, N.Y.). 7: 428. PMID 28224046 DOI: 10.7916/D8XD127W  0.182
2006 Greene PE, Dauer W. Stiff child syndrome with mutation of DYT1 gene [7] Neurology. 66: 1456. PMID 16682692 DOI: 10.1212/01.wnl.0000224700.52413.31  0.181
1998 Dauer WT, Burke RE, Greene P, Fahn S. Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. Brain : a Journal of Neurology. 121: 547-60. PMID 9577384 DOI: 10.1093/brain/121.4.547  0.177
2021 Yellajoshyula D, Pappas SS, Rogers AE, Choudhury B, Reed X, Ding J, Cookson MR, Shakkottai VG, Giger RJ, Dauer WT. THAP1 modulates oligodendrocyte maturation by regulating ECM degradation in lysosomes. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 34312226 DOI: 10.1073/pnas.2100862118  0.171
2008 Dauer W. Overview: Rodent and fish models of Parkinson's disease Parkinson's Disease. 219-223. DOI: 10.1016/B978-0-12-374028-1.00016-6  0.17
2021 Albin RL, Müller MLTM, Bohnen NI, Spino C, Sarter M, Koeppe RA, Szpara A, Kim K, Lustig C, Dauer WT. α4β2 Nicotinic Cholinergic Receptor Target Engagement in Parkinson Disease Gait-Balance Disorders. Annals of Neurology. PMID 33977560 DOI: 10.1002/ana.26102  0.166
2023 Hernandez-Ono A, Zhao YP, Murray JW, Östlund C, Lee MJ, Shi A, Dauer WT, Worman HJ, Ginsberg HN, Shin JY. Functional interaction of torsinA and its activators in liver lipid metabolism. Biorxiv : the Preprint Server For Biology. PMID 37547008 DOI: 10.1101/2023.06.21.545957  0.152
2004 Dauer W, Goodchild R. Mouse models of torsinA dysfunction Advances in Neurology. 94: 67-72. PMID 14509656  0.151
1994 Schwarzschild MA, Dauer WT, Lewis SE, Hamill LK, Fink JS, Hyman SE. Leukemia inhibitory factor and ciliary neurotrophic factor increase activated Ras in a neuroblastoma cell line and in sympathetic neuron cultures. Journal of Neurochemistry. 63: 1246-54. PMID 7523587 DOI: 10.1046/J.1471-4159.1994.63041246.X  0.151
1994 Lewis SE, Rao MS, Symes AJ, Dauer WT, Fink JS, Landis SC, Hyman SE. Coordinate regulation of choline acetyltransferase, tyrosine hydroxylase, and neuropeptide mRNAs by ciliary neurotrophic factor and leukemia inhibitory factor in cultured sympathetic neurons. Journal of Neurochemistry. 63: 429-38. PMID 7518494 DOI: 10.1046/J.1471-4159.1994.63020429.X  0.145
2015 Jankovic J, Bressman S, Dauer W, Kang UJ. Clinical and scientific perspectives on movement disorders: Stanley Fahn's contributions Movement Disorders. 30: 1862-1869. DOI: 10.1002/mds.26445  0.137
2007 Liu S, Fa M, Ninan I, Trinchese F, Dauer W, Arancio O. Alpha-synuclein involvement in hippocampal synaptic plasticity: role of NO, cGMP, cGK and CaMKII. The European Journal of Neuroscience. 25: 3583-96. PMID 17610578 DOI: 10.1111/J.1460-9568.2007.05569.X  0.133
2020 Kim S, Barmada S, Dauer W, Veatch S. Probing Neuronal Nuclear Pore Complexes Using Single Molecule Localization Microscopy Microscopy and Microanalysis. 26: 1034-1035. DOI: 10.1017/s1431927620016748  0.13
2022 Kim Y, Geng L, Lenhart AE, Li J, Dauer WT, Kennedy RT. Measurement of α-Synuclein Dynamics In Vivo Using Microdialysis with a Novel Homogeneous Immunoassay. Acs Chemical Neuroscience. PMID 35959902 DOI: 10.1021/acschemneuro.2c00251  0.129
2024 Hernandez-Ono A, Zhao YP, Murray JW, Östlund C, Lee MJ, Shi A, Dauer WT, Worman HJ, Ginsberg HN, Shin JY. Dynamic regulation of hepatic lipid metabolism by torsinA and its activators. Jci Insight. PMID 38194265 DOI: 10.1172/jci.insight.175328  0.127
2006 Weisstaub NV, Zhou M, Lira A, Lambe E, González-Maeso J, Hornung JP, Sibille E, Underwood M, Itohara S, Dauer WT, Ansorge MS, Morelli E, Mann JJ, Toth M, Aghajanian G, et al. Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science (New York, N.Y.). 313: 536-40. PMID 16873667 DOI: 10.1126/Science.1123432  0.116
2004 Liu S, Ninan I, Antonova I, Battaglia F, Trinchese F, Narasanna A, Kolodilov N, Dauer W, Hawkins RD, Arancio O. alpha-Synuclein produces a long-lasting increase in neurotransmitter release. The Embo Journal. 23: 4506-16. PMID 15510220 DOI: 10.1038/Sj.Emboj.7600451  0.112
2023 Holcomb JM, Chopra R, Feltrin FS, Elkurd M, El-Nazer R, McKenzie L, O'Suilleabhain P, Maldjian JA, Dauer W, Shah BR. Improving tremor response to focused ultrasound thalamotomy. Brain Communications. 5: fcad165. PMID 37533544 DOI: 10.1093/braincomms/fcad165  0.093
2022 Feltrin FS, Chopra R, Pouratian N, Elkurd M, El-Nazer R, Lanford L, Dauer W, Shah BR. Focused ultrasound using a novel targeting method four-tract tractography for magnetic resonance-guided high-intensity focused ultrasound targeting. Brain Communications. 4: fcac273. PMID 36751499 DOI: 10.1093/braincomms/fcac273  0.084
1998 Dauer WT, Fahn S, Burke RE. The Diagnosis and Treatment of Tardive Disorders Medical Update For Psychiatrists. 3: 119-125. DOI: 10.1016/S1082-7579(98)00016-8  0.051
2022 Bohnen NI, Costa RM, Dauer WT, Factor SA, Giladi N, Hallett M, Lewis SJG, Nieuwboer A, Nutt JG, Takakusaki K, Kang UJ, Przedborski S, Papa SM. Reply to: "Letter on Discussion of Gait Research". Movement Disorders : Official Journal of the Movement Disorder Society. 37: 1328. PMID 35707827 DOI: 10.1002/mds.29049  0.039
1983 Kleinmanns G, Dauer W, Knief JJ, Westerhausen M. [Therapeutic results in advanced ovarian cancer]. Onkologie. 6: 206-9. PMID 6415561 DOI: 10.1159/000215237  0.035
1999 Dauer W, Potschadtke J, Bolz A, Schaldach M. [Modeling intracardiac potentials using the finite element method]. Biomedizinische Technik. Biomedical Engineering. 320-1. PMID 9859380 DOI: 10.1515/bmte.1998.43.s1.320  0.022
1999 Bassel JR, Edwards A, Leibbrand L, Keller G, Dauer W. Three Road-Crushing Demonstration Projects Transportation Research Record: Journal of the Transportation Research Board. 1652: 192-195. DOI: 10.3141/1652-24  0.021
2014 Bohnen N, Sarter M, Muller M, Dauer W, Albin R. Author response. Neurology. 82: 1568-9. PMID 24895748 DOI: 10.1212/WNL.0000000000000607  0.01
Hide low-probability matches.